Graniforce Syrup contains Granisetron 1mg, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron acts by blocking serotonin receptors located on vagal nerve terminals and in the central nervous system, thereby inhibiting the emetic signal transmission to the vomiting center in the brain. This mechanism effectively reduces the incidence and severity of acute emesis. Graniforce Syrup is indicated for pediatric and adult patients who require an oral formulation for ease of administration. The syrup form allows for accurate dosing and improved compliance, especially in patients with difficulty swallowing tablets. It is generally well tolerated, with common adverse effects including headache, constipation, and transient elevation of liver enzymes. Graniforce Syrup should be used under medical supervision, with dosage adjustments based on patient response and clinical condition. Caution is advised in patients with hepatic impairment, and it should be used with care in individuals with a history of cardiac arrhythmias. Granisetron does not typically cause sedation or extrapyramidal symptoms, making it a preferred choice in supportive care for oncology patients.